This inventor holds 4 USPTO granted patents. Top assignee: Smithkline Beecham Corporation. Active years: 1994-1996.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1994-1996
Title: The Innovations of Philip L. Simon
Introduction
Philip L. Simon is a notable inventor based in Randolph, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit tumor necrosis factor (TNF) production. With a total of 4 patents to his name, Simon's work has the potential to impact the treatment of various disease states.
Latest Patents
Among his latest patents, Simon has developed derivatives of 2-pyrrolidinones that inhibit TNF production. These compounds are particularly useful in treating diseases that are mediated or exacerbated by TNF. His innovative approach to TNF inhibition showcases his commitment to advancing medical science and improving patient outcomes.
Career Highlights
Simon is associated with SmithKline Beecham Corporation, where he has been instrumental in research and development. His work has not only contributed to the company's portfolio but has also paved the way for new therapeutic options in the pharmaceutical industry.
Collaborations
Throughout his career, Simon has collaborated with esteemed colleagues such as Klaus M. Esser and Siegfried B. Christensen, IV. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Philip L. Simon's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work in TNF inhibition is a testament to his dedication to improving healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile